Graid Technology Announces SupremeRAID SE Support for the NVIDIA GeForce RTX 5000 Series, Expanding High-Performance RAID for Workstations
With Support for the NVIDIA® GeForce RTX™ 5090, 5080, 5070 Ti, 5070 and 5060, SupremeRAID™ SE Continues to Push the Boundaries of High-Performance Workstation Storage
SANTA CLARA, CALIFORNIA / ACCESS Newswire / February 13, 2025 / Graid Technology, the leader in GPU-based RAID solutions, today announced that SupremeRAID™ SE now supports the entire NVIDIA® GeForce RTX™ 5000 series, delivering unparalleled RAID performance to high-end workstation users. With support for the GeForce RTX 5090, 5080, 5070 Ti, 5070, and 5060, professionals can leverage NVIDIA's most powerful GPUs to maximize NVMe SSD performance with exceptional efficiency and resilience.
SupremeRAID™ SE is Graid Technology's bring-your-own-GPU RAID solution, designed for workstation users who demand high-speed data access, reliability, and flexibility. With support for the GeForce RTX 5000 series, users can take advantage of NVIDIA's cutting-edge Blackwell architecture and ultra-fast GDDR7 memory to eliminate RAID bottlenecks and unlock the full potential of NVMe SSD storage.
"With SupremeRAID™ SE, we're continuing to redefine what's possible for workstation RAID," said Leander Yu, President and CEO at Graid Technology. "By expanding support to the entire NVIDIA GeForce RTX 5000 series, we're giving professionals even greater flexibility to harness their GPU's power for extreme data performance - whether for AI, content creation or other demanding workloads."
SupremeRAID™ SE enables users to configure RAID across 4 to 8 NVMe SSDs, ensuring maximum throughput and resilience while freeing up CPU resources for other intensive tasks.
Key benefits of SupremeRAID™ SE with the NVIDIA GeForce RTX 5000 series include:
Unmatched AI and Compute Power - Leverages NVIDIA's Blackwell architecture for high-speed RAID processing.Support for the Latest GPUs - Now compatible with the GeForce RTX 5090, 5080, 5070 Ti, 5070, and 5060.Bring-Your-Own-GPU Flexibility - Users can maximize their investment by utilizing existing GPU hardware for RAID acceleration.Optimized for Extreme Workloads - Ideal for AI, machine learning, 3D rendering, video editing, and gaming development.Simplified, Software-Defined RAID - Easy configuration without the complexity of traditional hardware RAID solutions.
Join the SupremeRAID™ SE Beta ProgramGraid Technology continues to pioneer next-generation RAID solutions, reinforcing its position as a market leader. Users interested in experiencing SupremeRAID™ SE with the NVIDIA GeForce RTX 5000 series can sign up for the beta program at beta.graidtech.com.
About Graid TechnologyGraid Technology is transforming what's possible for high-performance computing. As the creator of SupremeRAID™, the world's first and only GPU-based RAID, the company is committed to helping enterprises unlock the full potential of their NVMe SSDs. Through global partnerships with industry leaders like NVIDIA, Supermicro, and Dell Technologies, Graid Technology delivers cutting-edge RAID solutions for AI, machine learning, media & entertainment, and high-performance computing. For more information, visit www.graidtech.com.
SOURCE: Graid Technology Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
BASF starts $6.8B sale of its coatings business, Bloomberg reports
BASF (BASFY) SE recently sent out information to potential suitors for of its coating business, in a process that could value the union at $6.8B, Dinesh Nair, Eyk Henning, Swetha Gopinath, and Pamela Barbaglia of Bloomberg reports, citing people familiar with the matter. Carlyle Group (CG) is considering bidding for the coating business with Sherwin-Williams (SHW), the sources added, Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Forbes
3 hours ago
- Forbes
The Strategy Behind Hugging Face's Acquisition Of Pollen Robotics
Reachy 2 In April 2025, Hugging Face acquired Pollen Robotics, a France-based company that develops humanoid robots, including Reachy 2. This marks a milestone in the convergence of generative AI and robotics, known as physical AI. This article analyzes the strategic reasons behind Hugging Face's acquisition of Pollen Robotics. Hugging Face's acquisition of Pollen Robotics demonstrates a long-term vision for the future of AI technology, as it evolves from digital intelligence to physical form. The strategy is based on three core pillars: 1) Vertical integration of the AI-to-robotics stack 2) Ecosystem leverage through their massive developer community 3) Timing advantage as foundation models become capable of controlling physical systems. The acquisition gives Hugging Face immediate access to Pollen's flagship Reachy 2 humanoid robot, a $70,000 research platform already deployed at prestigious institutions such as Cornell University and Carnegie Mellon. With 7 degrees of freedom, bio-inspired arms capable of handling 3 kg payloads, advanced VR teleoperation and fully open-source hardware designs, the Pollen Robotics Reachy 2 offers a proven platform for Hugging Face to build upon instead of starting from scratch. The timing proves particularly strategic given several converging factors. Nvidia recently chose Hugging Face as the preferred platform for its GR00T N1 humanoid robot foundation models, signalling industry recognition of Hugging Face's platform capabilities. Meanwhile, the remarkable growth of Hugging Face's LeRobot library to over 12,000 GitHub stars in just 12 months demonstrated strong developer demand for open robotics tools. The acquisition also follows Hugging Face's strategic hire of Remi Cadene, a former Tesla Optimus engineer, who now leads their robotics division. While Hugging Face has emerged as the largest collection of open-source and open-weight models, Pollen Robotics focuses on the vision of open hardware for robotics. This acquisition combines the strengths of open-source software with open hardware design in the field of robotics. The embodied AI market has reached an inflection point where theoretical capabilities meet practical applications, driven by breakthroughs in foundation models for robotics and dramatic cost reductions in hardware components. AI models such as Pi0 from Hugging Face, Nvidia's GR00T N1 and Google's Gemini Robotics extend the power of generative AI to robotics. Instead of generating text or media content, these models are trained to send commands directly to the robotic hardware. They leverage multimodal AI by combining video content and policies to generate commands that control robots. The combination of Hugging Face's AI infrastructure and Pollen's robotics expertise creates technical synergies that neither company could achieve independently. Hugging Face brings 1.5 million models and datasets hosted on its platform, proven infrastructure serving 12 petabytes of data, and deep expertise in transformer architectures and diffusion models. This AI foundation provides the intelligence layer essential for next-generation robotics. Hugging Face's acquisition of Pollen Robotics represents more than a product expansion. It marks a fundamental shift in how AI and robotics will evolve together. By combining proven AI infrastructure with capable robotics hardware under an open-source philosophy, Hugging Face creates unique value that neither pure software nor pure hardware companies can replicate. The broader implications extend beyond corporate strategy. If Hugging Face succeeds in democratizing robotics as they've democratized AI, we may see an explosion of innovation similar to what followed the open-sourcing of deep learning frameworks.
